Biodexa names Fiona Sharp as CFO and director

Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer, Corporate Secretary and member of the Board of Directors, effective January 5, 2026.

Rhea-AI Filing Summary

Biodexa Pharmaceuticals PLC has appointed Fiona Sharp as Chief Financial Officer, Corporate Secretary and member of the Board of Directors, effective January 5, 2026. She will serve as a director until the company’s annual general meeting in 2026, while Stephen Stamp continues as Chief Executive Officer after relinquishing the CFO and Corporate Secretary roles.

Sharp, aged 57, has been the company’s Group Financial Controller since December 2019 and previously held senior finance roles at Hywell DDA University Health Board and Chime Communications Limited. The company states that she has no family relationships with existing directors or executives, no selection arrangements with other parties, and no reportable transactions with the company. The appointment information is incorporated by reference into Biodexa’s existing Form S-8 and Form F-3 registration statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Biodexa Pharmaceuticals (BDRX) disclose in this Form 6-K?

Biodexa Pharmaceuticals PLC disclosed that it appointed Fiona Sharp as its Chief Financial Officer, Corporate Secretary, and a member of the Board of Directors, effective January 5, 2026.

What is Fiona Sharp’s term as a director at Biodexa Pharmaceuticals (BDRX)?

Fiona Sharp will serve as a director of Biodexa Pharmaceuticals PLC until the company’s annual general meeting in 2026.

What role does Stephen Stamp continue to hold at Biodexa Pharmaceuticals (BDRX)?

Stephen Stamp has relinquished his roles as Chief Financial Officer and Corporate Secretary but continues to serve as Chief Executive Officer of Biodexa Pharmaceuticals PLC.

What relevant experience does Fiona Sharp bring to Biodexa Pharmaceuticals (BDRX)?

Fiona Sharp has been Group Financial Controller of Biodexa since December 2019, previously served as Assistant Director of Finance for Hywell DDA University Health Board, and held multiple senior finance positions, including Group Finance Director, at Chime Communications Limited. She is also a Chartered Certified Accountant.

Does Biodexa Pharmaceuticals (BDRX) report any related-party transactions or family relationships for Fiona Sharp?

The company states that Fiona Sharp has no family relationships with its directors or executive officers, there are no arrangements or understandings with other persons regarding her selection, and there are no transactions with her that would be reportable under Form 20-F.

How is this leadership change used in Biodexa Pharmaceuticals’ (BDRX) existing registration statements?

The information about Fiona Sharp’s appointment in this report is incorporated by reference into Biodexa Pharmaceuticals PLC’s registration statements on Form S-8 (File No. 333-209365) and Form F-3 (File No. 333-290554).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/06/2026 - 04:05 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of January 2026

Commission File Number 001-37652

Biodexa Pharmaceuticals PLC

(Translation of registrant’s name into English)

1 Caspian Point,

Caspian Way

Cardiff, CF10 4DQ, United Kingdom

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F x      Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

Appointment of Fiona Sharp as Executive Officer and Director

As previously announced, on January 5, 2026, Biodexa Pharmaceuticals PLC (the “Company”) appointed Fiona Sharp as the Company’s Chief Financial Officer, Corporate Secretary and a member of the Board of Directors, effective immediately. Stephen Stamp, who relinquished his positions as the Company’s Chief Financial Officer and Corporate Secretary, will remain as Chief Executive Officer. Ms. Sharp shall serve as director for a term to expire at the Company’s annual general meeting in 2026.

Ms. Sharp, aged 57, has served as Group Financial Controller of the Company since December 2019. Prior to that, she served as Assistant Director of Finance for Hywell DDA University Health Board, the local health board of the National Health Service of Wales for western Wales, United Kingdom, from October 2018 to July 2019. From 1995 to June 2018, Ms. Sharp held various financial leadership roles with Chime Communications Limited, a London-based international communications and sports marketing group, including Group Tax Consultant and Group Finance Director. Ms. Sharp is a Chartered Certified Accountant.

Ms. Sharp does not have any family relationships with any of the Company’s directors or executive officers, there are no arrangements or understandings between Ms. Sharp and any other persons pursuant to which she was selected as an officer or director, and there are no transactions between Ms. Sharp and the Company that would be reportable pursuant to Form 20-F.

The information included in this report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File Number 333-209365) and Form F-3 (File Number 333-290554) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Biodexa Pharmaceuticals PLC
Date: January 6, 2026	By:	/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer